What is the SIRFLOX study?
SIRFLOX is an international research study that evaluated a new treatment option for patients with colorectal cancer that has spread to the liver. The study compared the results of adding Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres to a standard treatment with chemotherapy alone.
What did the SIRFLOX study show, and what could this mean for me?
The SIRFLOX study results indicate that, in patients just diagnosed with unresectable liver metastases from colorectal cancer, the addition of SIR-Spheres Y-90 resin microspheres to standard chemotherapy extends the time before tumours in the liver start to grow again. This is important because the liver is the main organ where colorectal cancer spreads to first and these liver tumours most often cause the patient’s health status to decline.
Based on these results, SIRT is a treatment option that can be offered to patients with colorectal cancer that has spread to the liver. Only your medical oncologist, in consultation with the multidisciplinary team, can assess if SIRT is right for you. Please contact your treating doctor to learn more about SIRT and the results of the SIRFLOX study.
The results of the SIRFLOX study suggest that SIRT with SIR-Spheres Y-90 resin microspheres can be considered for timely use in patients with colorectal cancer that has spread only or mainly to the liver.